NeuroBo Licenses NB-01 to MThera Pharma

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company specializing in cardiometabolic diseases, has entered into an exclusive license agreement with MThera Pharma Co., Ltd. (MTHERA). This agreement grants MTHERA the rights to NB-01, a potential treatment for painful diabetic neuropathy. Under the terms of the agreement, MTHERA will be responsible for research and clinical trials, including a possible Phase 3 clinical trial in the United States and South Korea, aimed at future commercialization of NB-01. The financial specifics of this deal remain undisclosed.

In a statement, Hyung Heon Kim, President and CEO of NeuroBo, emphasized the significance of this agreement for NB-01. He highlighted NeuroBo's strategic focus on out-licensing legacy assets, such as NB-01, to concentrate on the clinical development of its other candidates, DA-1726 and DA-1241. Kim noted that MTHERA's expertise in manufacturing, quality control, and the clinical development of natural and botanical medicines makes it an excellent partner for advancing NB-01.

Dr. Mi Won Sohn, CEO of MTHERA, expressed optimism about the partnership, referencing the positive Phase 2 efficacy results for NB-01 in treating diabetic neuropathy. Dr. Sohn emphasized the potential of NB-01 to become a treatment for peripheral diabetes. Utilizing MTHERA's SyMthomics platform technology, the company aims to identify the mechanism of action and active ingredients in NB-01 to predict its clinical efficacy as an innovative treatment. Dr. Sohn conveyed gratitude to NeuroBo for the chance to further develop NB-01 and potentially bring this promising therapy to patients needing it.

MThera Pharma Co., Ltd., headquartered in Seoul, South Korea, is a biopharmaceutical company dedicated to developing first-in-class botanical drug products. These products utilize novel, multi-component, and multi-target-driven therapies designed to modify diseases and address various chronic, incurable conditions such as Parkinson's disease, dementia, and inflammatory bowel disease. MTHERA's SyMthomics platform incorporates the MThera-CODA system, an AI-based in silico system, multi-omics integration technology, systems biology, and bioinformatics. MTHERA also employs standardization and advanced CMC technology to ensure therapeutic consistency that meets U.S. Food and Drug Administration standards.

NeuroBo Pharmaceuticals, Inc. is a company focused on transforming cardiometabolic diseases. The company's current focus includes developing DA-1726 and DA-1241. DA-1726 is an oxyntomodulin (OXM) analogue that acts as a dual agonist for glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). This dual action decreases food intake while increasing energy expenditure, potentially resulting in superior weight loss compared to selective GLP1R agonists. DA-1241 is a G-protein-coupled receptor 119 (GPR119) agonist that facilitates the release of essential gut peptides GLP-1, GIP, and PYY. Pre-clinical studies of DA-1241 have shown positive effects on liver inflammation, lipid metabolism, weight loss, and glucose metabolism. These studies indicated reductions in hepatic steatosis, hepatic inflammation, and liver fibrosis, along with improvements in glucose control.

In conclusion, the agreement between NeuroBo and MTHERA represents a significant step forward in the development of NB-01 for treating painful diabetic neuropathy. Both companies bring a wealth of expertise and technology to the table, promising potential advancements in the treatment of this condition. NeuroBo remains committed to focusing on its core projects while leveraging strategic partnerships to advance other promising treatments.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!